Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

PHASE2RecruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

March 6, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2029

Conditions
Autosomal Dominant Polycystic KidneyObesity
Interventions
DRUG

Tirzepatide

Titrated to dose of 5 mg once weekly subcutaneous

OTHER

Placebo

Titrated to dose of 5 mg once weekly subcutaneous

Trial Locations (1)

80045

RECRUITING

University of Colorado - Anschutz Medical Campus, Aurora

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Washington University School of Medicine

OTHER

collaborator

Mayo Clinic

OTHER

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Colorado, Denver

OTHER

NCT06582875 - Glucagon-Like Peptide-1 Receptor Agonist in ADPKD | Biotech Hunter | Biotech Hunter